Repligen Management

Management criteria checks 3/4

Repligen's CEO is Tony Hunt, appointed in May 2015, has a tenure of 8.92 years. total yearly compensation is $7.71M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth R$89.57M. The average tenure of the management team and the board of directors is 2.6 years and 8.1 years respectively.

Key information

Tony Hunt

Chief executive officer

US$7.7m

Total compensation

CEO salary percentage	10.4%
CEO tenure	8.9yrs
CEO ownership	0.2%
Management average tenure	2.6yrs
Board average tenure	8.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tony Hunt's remuneration changed compared to Repligen's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$42m
Sep 30 2023	n/a	n/a	US$116m
Jun 30 2023	n/a	n/a	US$138m
Mar 31 2023	n/a	n/a	US$168m
Dec 31 2022	US$8m	US$800k	US$186m
Sep 30 2022	n/a	n/a	US$166m
Jun 30 2022	n/a	n/a	US$159m
Mar 31 2022	n/a	n/a	US$146m
Dec 31 2021	US$8m	US$761k	US$128m
Sep 30 2021	n/a	n/a	US$119m
Jun 30 2021	n/a	n/a	US$100m
Mar 31 2021	n/a	n/a	US$80m
Dec 31 2020	US$5m	US$725k	US$60m
Sep 30 2020	n/a	n/a	US$44m
Jun 30 2020	n/a	n/a	US$31m
Mar 31 2020	n/a	n/a	US$23m
Dec 31 2019	US$4m	US$685k	US$21m
Sep 30 2019	n/a	n/a	US$23m
Jun 30 2019	n/a	n/a	US$27m
Mar 31 2019	n/a	n/a	US$21m
Dec 31 2018	US$14m	US$600k	US$17m
Sep 30 2018	n/a	n/a	US$23m
Jun 30 2018	n/a	n/a	US$23m
Mar 31 2018	n/a	n/a	US$29m
Dec 31 2017	US$3m	US$550k	US$28m

Compensation vs Market: Tony's total compensation ($USD7.71M) is above average for companies of similar size in the BR market ($USD5.73M).

Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.

CEO

Tony Hunt (59 yo)

8.9yrs

Tenure

US$7,713,930

Compensation

Mr. Anthony J. Hunt, also known as Tony, serves as Director at 908 Devices Inc. since March 2, 2022. He has been the Chief Executive Officer of Repligen Corporation since May 21, 2015 and served as its Pre...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Anthony Hunt	CEO & Director	8.9yrs	US$7.71m	0.17% $ 89.6m
James Bylund	Chief Operating Officer	4.1yrs	US$2.38m	0.038% $ 19.6m
Christine Gebski	Senior Vice President of Filtration & Chromatography	3.8yrs	US$1.64m	0.050% $ 25.9m
Ralf Kuriyel	Senior Vice President of Research & Development	7.5yrs	US$1.68m	0.032% $ 16.5m
Olivier Loeillot	President & Chief Commercial Officer	less than a year	no data	no data
Jason Garland	Chief Financial Officer	less than a year	no data	no data
Keith Robinson	Chief Information Officer	no data	no data	no data
Sondra Newman	Global Head of Investor Relations	no data	no data	no data
Kimberly Cornwell	General Counsel	no data	no data	no data
Jaime Humara	Senior Vice President of Marketing	no data	no data	no data
Neil Whitfield	Vice President of Sales	1.5yrs	no data	no data
Leslie Galvin	Global Head of Human Resources	1.3yrs	no data	no data

2.6yrs

Average Tenure

59yo

Average Age

Experienced Management: R2GE34's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Anthony Hunt	CEO & Director	8.9yrs	US$7.71m	0.17% $ 89.6m
Glenn Muir	Independent Director	8.5yrs	US$270.00k	0.012% $ 6.4m
Charles Leland Cooney	Member of Scientific Advisory Board	8.1yrs	no data	no data
Martin Madaus	Independent Director	1.2yrs	no data	0.0029% $ 1.5m
Karen Dawes	Independent Chairperson of the Board	18.6yrs	US$381.98k	0.16% $ 80.7m
Carrie Eglinton Manner	Independent Director	3.8yrs	US$395.92k	0.0038% $ 2.0m
J. Love	Member of Scientific Advisory Board	8.1yrs	no data	no data
Konstantin Konstantinov	Member of Scientific Advisory Board & Independent Director	8.1yrs	US$399.95k	0% $ 0
Steven Cramer	Member of Scientific Advisory Board	8.1yrs	no data	no data
Rohin Mhatre	Independent Director	4.1yrs	US$452.54k	0.0030% $ 1.5m
Richard Braatz	Member of Scientific Advisory Board	no data	no data	no data
Nicholas Barthelemy	Independent Director	9.8yrs	US$255.00k	0.0037% $ 1.9m

8.1yrs

Average Tenure

63yo

Average Age

Experienced Board: R2GE34's board of directors are considered experienced (8.1 years average tenure).

Repligen Management

Management criteria checks 3/4

Key information

Recent management updates

Repligen Corporation Announces Management Changes, Effective September 1, 2024

Repligen Corporation, Annual General Meeting, May 16, 2024

Repligen Corporation Appoints Maggie A. Pax as Board of Directors

Repligen Corporation Appoints Olivier Loeillot as President and Chief Commercial Officer

Repligen Corporation Appoints Jason K. Garland as Chief Financial Officer Effective September 25, 2023

Repligen Appoints Martin D. Madaus to Board of Directors

Recent updates

Repligen Corporation Announces Management Changes, Effective September 1, 2024

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

Repligen Corporation to Report Q1, 2024 Results on May 01, 2024

Repligen Corporation, Annual General Meeting, May 16, 2024

Repligen Corporation Appoints Maggie A. Pax as Board of Directors

Repligen Corporation Provides Earnings Guidance for the Year 2024

Repligen Corporation to Report Q4, 2023 Results on Feb 21, 2024

Repligen Corporation announced that it has received $290.1 million in funding

Repligen Corporation announced that it expects to receive $290.1 million in funding

Repligen Corporation announced that it expects to receive $290.1 million in funding

Repligen Corporation Launches TangenX®? SC as First-To-Market Holder-Free Self-Contained TFF Device

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023

Repligen Corporation to Report Q3, 2023 Results on Oct 31, 2023

Repligen Corporation Appoints Olivier Loeillot as President and Chief Commercial Officer

Repligen Corporation (NasdaqGS:RGEN) entered into a definitive agreement to acquire Metenova AB.

Repligen Corporation Appoints Jason K. Garland as Chief Financial Officer Effective September 25, 2023

Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023

Repligen Appoints Martin D. Madaus to Board of Directors

Repligen Corporation to Report Q4, 2022 Results on Feb 22, 2023

Repligen Corporation Revises Earnings Guidance for the Year Ending December 31, 2022

Repligen Corporation to Report Q3, 2022 Results on Nov 01, 2022

Repligen Corporation Revises Earnings Guidance for the Fiscal Year 2022

Repligen Corporation to Report Q2, 2022 Results on Aug 02, 2022

Repligen Corporation Appoints Konstantin Konstantinov to Board of Directors

Repligen Corporation to Report Q1, 2022 Results on Apr 27, 2022

Repligen Corporation, Annual General Meeting, May 26, 2022

Repligen Corporation Provides Earning Guidance for 2022

Repligen Corporation Announces Commercial Launch of Three Advanced Affinity Chromatography Resins for Use in Gene Therapy Manufacturing Workflows

Repligen Corporation to Report Q4, 2021 Results on Feb 17, 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age